Diseases & Longevity · File 17

Mild cognitive impairment. 30-50% progress to dementia in 5 years — the window for action.

Mild cognitive impairment (MCI) is the intermediate stage between cognitive normality and dementia — cognitive complaints with altered objective performance but without significant compromise of activities of daily living. Approximately 30-50% of MCI patients progress to dementia in 5 years, but a significant proportion also reverts or stabilizes. That is the window where longevity medicine operates with greatest power of modification.

Why MCI is the stage where cognitive longevity is decided

MCI is the last stage before clinical dementia diagnosis where modifiable intervention has significant impact. The 5-year trajectory is heterogeneous: ~30-50% progress to dementia (Alzheimer, vascular, frontotemporal, Lewy bodies), ~30-40% remain stable, and ~15-25% revert to cognitive normality. That heterogeneity is exactly what justifies a structured longevity medicine view — not all MCI are equal.

The Lancet Commission 2024 identified 14 modifiable factors explaining ~45% of population dementia risk — including HTN, uncorrected hearing loss, untreated depression, social isolation, physical inactivity, diabetes, obesity, smoking, excessive alcohol, high LDL, air pollution, low education, uncorrected visual loss, and traumatic brain injury. In MCI those 14 factors are the central target. Their management does not guarantee non-progression — but significantly changes the odds.

MCI is not "a little dementia" — it is the modifiable window par excellence. Working the 14 factors changes real trajectories.
MCI → dementia conversion in 5y

The global weight, in numbers

Quantitative MCI data come from Mayo Clinic cohort, ADNI, European cohorts, and longitudinal meta-analyses. Trajectory heterogeneity is robust across cohorts.

  • Prevalence in >65

    ~10-20%

    MCI prevalence in adults over 65 is approximately 10-20% according to criteria and cohort. Increases significantly with age — exceeds 25% in >80.
    — Petersen et al., Continuum 2018

  • Conversion to dementia

    30-50% a 5 años

    Approximately 30-50% of MCI patients progress to clinical dementia in 5 years. Amnesic subgroup (aMCI) has higher conversion rate to Alzheimer; non-amnesic predicts more non-Alzheimer dementia.
    — Petersen Continuum 2018; Mayo Clinic Study of Aging

  • Reversion to normality

    15-25%

    A significant proportion (~15-25%) reverts to cognitive normality — usually when there are modifiable secondary causes (depression, hypothyroidism, B12 deficiency, OSA, anticholinergic drugs). Identifying them in time changes trajectory.
    — Roberts et al., Mayo Clinic Proc 2014

  • 45% modifiable risk

    14 factores · Lancet 2024

    Lancet Commission 2024 identifies 14 modifiable factors explaining ~45% of population dementia risk. In MCI they are the central intervention target.
    — Livingston et al., Lancet 2024

Chap. 03 · Cognitive and functional trajectory

Impact on quality of life and autonomy

MCI is not asymptomatic — it affects quality of life, confidence, productivity, and mental health, even though activities of daily living are preserved. Its early management changes that trajectory.

  • Subjective cognitive complaints

    Marcador clínico relevante

    Subjective cognitive complaints — perceptible by patient or close family — predict MCI and future dementia, even when cognitive tests are normal (subjective cognitive decline, SCD). Taking them seriously changes management.
    — Jessen et al., Alzheimer Dement 2014

  • Anxiety and depression

    Comorbilidad bidireccional

    MCI patients have higher frequency of anxiety and depression — both can be cause, consequence, or both. Their management is not optional: untreated depression accelerates cognitive deterioration and anxiety affects test performance.
    — Lancet Commission 2024

  • Loss of confidence and perceived autonomy

    Pre-clínico pero relevante

    MCI affects self-confidence, work productivity, complex decision-making, and quality of life — even when basic ADL are preserved. Structured clinical support changes that perception.
    — Mayo Clinic Study of Aging

  • Family and partner burden

    Anticipatoria

    Family and partner of MCI patient often live with anticipatory anxiety of future dementia diagnosis. Structured clinical support and clear information significantly change that experience.
    — Mosley et al., Maturitas 2017

What we don't offer — and what we do

Wellness Care does not diagnose dementia or MCI with the neurologist's final authority. Formal neuropsychological tests, Alzheimer-specific biomarkers (amyloid PET, CSF p-tau, monoclonal antibodies), and final clinical decision belong to the specialist. What we do is what the conventional system rarely integrates: structured evaluation of subjective cognitive concern, identification of modifiable causes, and intervention on the 14 Lancet Commission factors.

We evaluate patients with subjective cognitive concern, family history of dementia, multiple cardiovascular risk factors (HTN, T2D, dyslipidemia), persistent depression, social isolation, uncorrected hearing loss, or nonspecific complaints. Evaluation includes standardized cognitive tests, advanced biomarker profile (inflammaging, brain metabolic profile, microbiota, neuro profile when applicable), evaluation of the 14 modifiable factors, and individualized protocol design. Coordinated with neurology when indicated.

MCI is the window. We don't promise to prevent dementia, but the 14 modifiable factors are measurable and workable — and that changes real trajectories.
How we measure it

How MCI is evaluated
at Wellness Care

Four convergent layers — cognitive tests + advanced biomarkers + 14 Lancet Commission factors + systemic comorbidities. Neurology coordination always.

Advanced biomarkers

21 specialized panels across 8 clinical categories — biological age, inflammaging, metabolic profile, functional hormonal, microbiota. The quantitative layer.

Explore →

Alzheimer & AMBAR study

The largest Phase IIb/III trial of plasma exchange with albumin in Alzheimer's — Boada et al., Alzheimer's & Dementia 2020.

Explore →

Therapeutic plasma exchange

Spectra Optia, Buck Institute evidence (Fuentealba 2025), inflammaging modulation, and peripheral clearance.

Explore →

The Longevity Program

How this assessment integrates into the full program — from initial valuation to individualized protocol design under medical judgment.

Explore →
Featured evidence

Key evidence supporting this approach

Four publications structuring the MCI conversation in longevity medicine — Petersen Continuum, Lancet Commission 2024, SCD, and reversion to normality.

«El deterioro cognitivo leve es un estadio intermedio entre la cognición normal y la demencia, con tasas de conversión a demencia del 30-50% en 5 años — y de reversión a normalidad del 15-25%.»
Continuum · 2018
Petersen et al., Continuum 2018
Trayectoria heterogénea del MCI
«14 factores modificables explican aproximadamente el 45% del riesgo poblacional de demencia — en MCI son la diana central de la intervención.»
Lancet · 2024
Livingston et al., Lancet 2024
Lancet Commission · 14 factores
«El subjective cognitive decline (SCD) es un marcador clínico relevante de riesgo futuro — predice MCI y demencia incluso con tests cognitivos normales.»
Alzheimer Dement · 2014
Jessen et al., Alzheimer Dement 2014
SCD como predictor

Frequently asked questions about mild cognitive impairment

The most recurrent questions about MCI, its diagnosis, the heterogeneous trajectory, and why longevity medicine acts at this stage with power of modification.

01

How is MCI diagnosed?

Petersen criteria (NIA-AA 2011) require:

1. Subjective cognitive complaint or reported by informant
2. Objectively altered cognitive performance in one or more areas:

· Memory
· Executive function
· Language
· Visuospatial

3. General preservation of activities of daily living
4. Not meeting dementia criteria

Formal diagnosis requires structured neuropsychological evaluation — neurologist / neuropsychologist competence.

02

Which reversible MCI causes should be ruled out?

Modifiable or reversible causes to always evaluate:

· Clinical depression — can mimic MCI (pseudodementia)
· Hypothyroidism
· B12 / folate deficiency
· Obstructive sleep apnea
· Anemia
· Hyperhomocysteinemia
· Anticholinergic drugs — sedating H1 antihistamines, TCA, oxybutynin
· Alcohol
· Normal pressure hydrocephalus
· Neurosyphilis
· Nutritional deficiencies

Identifying and treating them can revert MCI to normality.

03

Which cognitive tests are used in initial evaluation?

Most used screening tests:

· MoCA (Montreal Cognitive Assessment) — more sensitive than classical MMSE for MCI, particularly in executive function
· Clinical dementia rating (CDR)
· Verbal fluency — semantic and phonological
· Boston Naming Test (BNT) — when aphasia is suspected
· Specific executive function — Trail Making, Stroop

Formal neuropsychological evaluation is more detailed and performed by a specialist.

04

Do p-tau and NfL biomarkers help in MCI?

Yes, although their interpretation is nuanced.

Plasma p-tau 217:

· Has consolidated as one of the most useful biomarkers to differentiate Alzheimer MCI (vs non-Alzheimer)
· Its elevation predicts progression
· Orients consideration of anti-amyloid treatments

NfL (neurofilament light chain):

· Nonspecific marker of axonal neuronal damage
· Useful for progression follow-up

Both require integrated clinical interpretation and are the neurologist's competence.

05

When should I consult?

A structured assessment is worthwhile if:

· You or your family notice persistent cognitive changes (memory, words, planning)
· Family history of dementia
· Multiple cardiovascular risk factors
· Persistent depression
· Uncorrected hearing loss
· History of TBI or occupational toxin exposure
· Want to evaluate your cognitive trajectory before clear symptoms

The assessment complements the neurologist — does not replace them.

The modifiable window par excellence

MCI is not "a little dementia" — it is the modifiable window par excellence. Working the 14 factors changes real trajectories.

Rule out reversible causes, measure advanced biomarkers, work the 14 Lancet Commission factors rigorously, and coordinate with neurology — that is what's missing in the conventional model.

Subjective cognitive concern or perceived changes?

Book a comprehensive cognitive assessment

We evaluate clinical history, standardized cognitive tests (MoCA, BNT, fluency, executive function), neuro-specific profile (p-tau, NfL when applicable), inflammaging and brain metabolic biomarkers, the 14 modifiable factors, and comorbidities. The assessment does not replace neurology or neuropsychology — it complements them.

Book cognitive assessment